|
Study procedures
|
Baseline
|
Treatment period
|
Follow-up period
|
|---|
|
Time point
|
0
|
3-month
|
6-month
|
12-month
|
|---|
|
Outcome measures
| | | | |
|
Clinical data
|
√
| | | |
|
Coronary artery CT
|
√
| |
√
| |
|
CRP
|
√
| |
√
| |
|
Therapeutic evaluation
|
|
Blood lipids
|
√
| |
√
| |
|
SAQ
|
√
|
√
|
√
|
√
|
|
Scores of CM symptoms
|
√
|
√
|
√
|
√
|
|
ALT, AST
|
√
| |
√
| |
|
Creatinine, blood urea nitrogen
|
√
| |
√
| |
|
Safety indicators
|
|
Blood glucose
|
√
| |
√
| |
|
Drug interaction
|
√
|
√
|
√
|
√
|
|
Adverse event
| |
√
|
√
|
√
|
|
Compliance observation
| |
√
|
√
|
√
|
|
Medicine treatment
|
√
|
√
|
√
|
√
|
- Note: CRP C-reactive protein, CT computed tomography, SAQ The Seattle Angina Questionnaire, CM Chinese medicine, ALT alanine aminotransferase, AST aspartate aminotransferase
